

EFFECT OF TENOFOVIR ALAFENAMIDE INITIATION ON LIPID PROFILE IN LA PAZ HOSPITAL COHORT: CONSEQUENCE OF TDF WITHDRAWAL OR TAF INITIATION?

Montejano, Rocio¹; Alejos, Belen²; De Miguel, Rosa¹; Moreno, Victoria¹; Valencia, Eulalia¹; Martin-Carbonero, Luz¹; Montes, M Luisa¹; Busca, Carmen¹; Mican, Rafael¹; Perez-Valero, Ignacio¹; Gonzalez-Garcia, Juan¹; Arribas, Jose R¹; Bernardino, Jose I¹

¹Hospital La Paz HIV Unit Madrid Spain; ²Instituto Salud Carlos III Thematic Networking (RETICS) Madrid Spain;


BACKGROUND

- Tenofovir alafenamide (TAF) is increasingly substituting tenofovir disoproxil fumarate (TDF) because its advantages on renal function and bone mineral density.
- TDF has a well-known lipid lowering effect and switching to TAF based regimens has been associated with increases in cholesterol fractions in pivotal clinical trials.

OBJECTIVES

- The objective of this study was to assess if lipid changes after TAF initiation are consequence of TDF withdrawal or TAF initiation.
- To evaluate changes in lipid profile after switching from standard ART regimen

RESULTS




Lipid profile changes in follow-up by group

24 Weeks (N=152) 48 Weeks (N=290)

	ABC/3TC	Nuke-Sparing	TDF/FTC	p-value	ABC/3TC	Nuke-Sparing	TDF/FTC	p-value
TC	+5.2±22.9	+40±57.1	+22.6±29.8 *	0.08	+16.4±33.1*	-4.9±30.7	+23.29±41.4*	0.01
HDL	-1.2±7.6	-0.4±9.05	+3.75±9 *	0.177	+0.3±9.1	+3.2±7.8	+3.0±9.2 *	0.38
LDL	+2.44±18.8	+32±60.3	+14±23.6 *	0.111	+5.41±28.6	-7.1±23.1	+16.8±27.9 *	0.001
TC:HDL	+0.2±0.34	+0.9±1.1	+0.04±0.99	0.12	+0.29±0.79	-0.6±0.6 *	+0.28±1.28 *	0.01
TG	+22.5±43.6	+35.2±37.4	+9.81±58.26	0.52	+13.7±45.3	-10.7±64.2	+24.9±83.4*	0.21
GLU	-0.8±9.9	+8.66±8.21*	-0.15±12.4	0.217	-0.6±11.4	+10.9±15.1*	-0.4±12.1	0.001


(Mean±SD) Expressed as mg/dl, * intragroup significant increase

Lipid profile changes in follow-up by group at Week 24 (Mean±SD)



At Week 24, there was a significant increase in TC +22.1±31.1 mg/dl, HDL +3.3±8.9 mg/dl, LDL +14.0±25.4 mg/dl, TG +11.5±56.9 while no changes in TC:HDL ratio.

Lipid profile changes in follow-up by group at Week 48 (Mean±SD)



At Week 48, there was a significant increase in TC +20.9±40.7 mg/dl, HDL +2.7±9.2 mg/dl, LDL +14.5±28.31mg/dl, TG +22.0±80.4 and TC:HDL +0.23±1.2.

CONCLUSIONS

These data suggest worsening lipid profiles after switching to TAF, mainly driven by TDF withdrawal.

Initial changes in lipids profile remain stable during the follow-up.

These results should be taken with caution due to small numbers and concomitant TAF and cobicistat use and lack of data regarding concomitant statins prescription.